Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Prothena Corporation plc (PRTA : NSDQ)

• Company Description    Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements. Number of Employees: 163

• Price / Volume Information    Yesterday's Closing Price: $9.55 Daily Weekly Monthly 20 Day Moving Average: 686,300 shares Shares Outstanding: 53.83 (millions) Market Capitalization: $514.08 (millions) Beta: -0.09 52 Week High: $16.67 52 Week Low: $4.32 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.43% -14.28% 12 Week -7.28% -8.78% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS - DUBLIN,L2 D02 VK60 IRL ph: 011-353-1236-2500 fax: 353-1902-3510 mark.johnson@prothena.com http://www.prothena.com

• General Corporate Information    Officers Gene G. Kinney - Chief Executive Officer and President Daniel G. Welch - Chair of the Board Tran B. Nguyen - Chief Financial Officer Paula K. Cobb - Director Richard T. Collier - Director Peer Information Prothena Corporation plc (CORR.) Prothena Corporation plc (RSPI) Prothena Corporation plc (CGXP) Prothena Corporation plc (BGEN) Prothena Corporation plc (GTBP) Prothena Corporation plc (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G72800108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/19/26 Share - Related Items Shares Outstanding: 53.83 Most Recent Split Date: (:1) Beta: -0.09 Market Capitalization: $514.08 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.39 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.20 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 23.41% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/19/26

• Fundamental Ratios P/E Current FY Estimate: 47.28 Trailing 12 Months: - PEG Ratio: 2.02 Price Ratios Price/Book: 1.74 Price/Cash Flow: - Price / Sales: 43.62 EPS Growth vs. Year Ago Period: 39.09% vs. Previous Quarter: 63.98% Sales Growth vs. Year Ago Period: 148.97% vs. Previous Quarter: -45.36% ROE 12/31/25 - - 09/30/25 - -65.89 06/30/25 - -62.17 ROA 12/31/25 - - 09/30/25 - -56.70 06/30/25 - -54.43 Current Ratio 12/31/25 - - 09/30/25 - 6.61 06/30/25 - 5.68 Quick Ratio 12/31/25 - - 09/30/25 - 6.61 06/30/25 - 5.68 Operating Margin 12/31/25 - - 09/30/25 - -2,157.81 06/30/25 - -2,680.19 Net Margin 12/31/25 - - 09/30/25 - -2,379.59 06/30/25 - -2,929.30 Pre-Tax Margin 12/31/25 - - 09/30/25 - -2,025.72 06/30/25 - -2,530.46 Book Value 12/31/25 - - 09/30/25 - 5.48 06/30/25 - 6.03 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©